Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

Executive Summary

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.

You may also be interested in...



How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value

With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.

QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula

Study in late-line use of heavily pretreated ovarian cancer may bring labeling closer in line with competitors, yet with limited commercial impact, analysts say.

Buoyed By US Tax Reform, Merck Plans $12bn In Capital Investments

Keytruda had a great year in 2017 with $3.8bn in sales, but some Merck investors would like to see more M&A activity to bolster the company's pipeline, relaxing dependency on the blockbuster PD-1 inhibitor. However, the company revealed $12bn in capital investments to support planned growth.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099335

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel